Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment
- Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy | Vertex Pharmaceuticals Newsroom Vertex Pharmaceuticals
- Vertex shares pop after nonopioid painkiller posts positive midstage trial results CNBC
- Vertex’s non-opioid drug reduces nerve pain in trial, shares hit record high Reuters
- Vertex Pharmaceuticals Shares Jump After Promising Study Results for Pain Medication The Wall Street Journal
- Vertex Stock Breaks Out On Phase 2 Results For Opioid Alternative Investor’s Business Daily
Read More: Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment